Adagio Medical shares extend rally with 22% after-hours jump to $0.46
AI Market Summary
Adagio Medical surged after reporting first patient treatment with its next-generation ULTA cryoablation system and preclinical data indicating 50%–75% shorter ablation times, alongside FDA clearance to expand its pivotal FULCRUMVT trial. Management also reiterated expectations for FDA approval of the first-generation ULTA system in coming months. The news improves near-term regulatory and clinical visibility, though the micro-cap profile and weak 12-month performance keep risk elevated.
Impact level
● Medium
Affected assets
NCSKS2USD/USDT+3.58%
AI Insight · NCSKS2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Adagio Medical (ADGM) rose more than 21% in the regular session and added another 22% after hours, ending at $0.46. The company said preclinical data for its next-generation cryoablation system suggest ablation time could be cut by 50% to 75%, potentially saving up to 30 minutes per procedure. Adagio also said it expects FDA approval for its first-generation ULTA system in the coming months. The company’s market capitalization is about $10.17 million, while the stock is down 66.42% over the past 12 months.
